The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Cytokine activate T-cell based compositions. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Cytokine-activated T-cell based compositions is a key innovation area in pharmaceuticals
Cytokines are proteins secreted by certain immune and non-immune cells, which influence the immune system. Certain cytokines trigger the immune system, while others pacify it. They help the body fight cancer, infections, and other diseases.T cells are the major effector cells in cellular immunity, produce cytokines in immune responses to mediate inflammation and regulate other types of immune cells. There are two types of T-cells: Killer T-Cells and Helper T-cells.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 320+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cytokine-activated T-cell based compositions.
Key players in cytokine-activated T-cell based compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to cytokine-activated T-cell based compositions
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Immatics||2090||Unlock company profile|
|Bristol-Myers Squibb||844||Unlock company profile|
|Cellectis||515||Unlock company profile|
|Fred Hutchinson Cancer Research Center||470||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||457||Unlock company profile|
|Iovance Biotherapeutics||335||Unlock company profile|
|Autolus||330||Unlock company profile|
|City of Hope||320||Unlock company profile|
|Gilead Sciences||303||Unlock company profile|
|bluebird bio||282||Unlock company profile|
|ImmunityBio||248||Unlock company profile|
|Miltenyi Biotec||207||Unlock company profile|
|Seattle Children's Hospital||199||Unlock company profile|
|CARsgen Therapeutics||167||Unlock company profile|
|Pfizer||146||Unlock company profile|
|Eureka Therapeutics||146||Unlock company profile|
|CRISPR Therapeutics||124||Unlock company profile|
|BioNTech||124||Unlock company profile|
|Adaptimmune Therapeutics||124||Unlock company profile|
|United States Of America||121||Unlock company profile|
|Allogene Therapeutics||114||Unlock company profile|
|Massachusetts General Hospital||111||Unlock company profile|
|Nanjing Legend Biotech||110||Unlock company profile|
|Precision Biosciences||107||Unlock company profile|
|Poseida Therapeutics||101||Unlock company profile|
|PT Soho Global Health Tbk||95||Unlock company profile|
|Sangamo Therapeutics||93||Unlock company profile|
|Immunovative Therapies||91||Unlock company profile|
|Innovative Cellular Therapeutics||86||Unlock company profile|
|Green Cross Holdings||78||Unlock company profile|
|F. Hoffmann-La Roche||75||Unlock company profile|
|Helmholtz Association of German Research Centres||74||Unlock company profile|
|Editas Medicine||73||Unlock company profile|
|Amgen||69||Unlock company profile|
|Immunocore Holdings||68||Unlock company profile|
|Fate Therapeutics||67||Unlock company profile|
|Celularity||67||Unlock company profile|
|St. Jude Children’s Research Hospital||65||Unlock company profile|
|Instil Bio||60||Unlock company profile|
|Adicet Bio||59||Unlock company profile|
|Intima Bioscience||58||Unlock company profile|
|MediGene||57||Unlock company profile|
|Bellicum Pharmaceuticals||57||Unlock company profile|
|Precigen||56||Unlock company profile|
|Shanghai Unicar-Therapy Bio-Medicine Technology||55||Unlock company profile|
|Mayo Clinic||54||Unlock company profile|
|TCR2 Therapeutics||54||Unlock company profile|
|TC BioPharm (Holdings)||53||Unlock company profile|
|Gracell Biotechnologies||52||Unlock company profile|
|Genscript Biotech||50||Unlock company profile|
Source: GlobalData Patent Analytics
Immatics is one of the leading patent filers for cytokine-activated T-cell based compositions. Immatics is a biopharmaceutical company focused on the development of T-cell immunotherapies to fight against cancer. Immatics combines the discovery of targets for cancer immunotherapies with the right T-cell receptors enabling a robust and specific T-cell response against the selected targets.
In terms of application diversity, Mycenax Biotech is the top company, followed by AiCuris Anti-infective Cures and MediGene. By means of geographic reach, Otsuka holds the top position, while ImmunityBio and AbbVie stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.